Jan Kaiserle

Jan Kaiserle

Medical Systems Advisor
Jan Kaiserle specializes in medical research and evidence-based medicine. He explores the latest advancements in medical science, clinical trials, and healthcare technologies to improve diagnosis, treatment, and disease prevention. His content bridges the gap between clinical research and practice, providing meaningful insights for healthcare professionals.
FDA Explores AI Risks in Digital Mental Health Devices
Management & Administration FDA Explores AI Risks in Digital Mental Health Devices

The intersection of artificial intelligence and mental health care is sparking both excitement and concern, as cutting-edge technologies promise to revolutionize access to support while raising critical questions about safety and efficacy. On a recent November day, the US Food and Drug

Healthcare Dealmakers: Samaritan Joins MultiCare and More
Management & Administration Healthcare Dealmakers: Samaritan Joins MultiCare and More

The healthcare sector is undergoing a remarkable transformation as organizations across the spectrum—from hospitals to tech firms and retail pharmacies—engage in a flurry of mergers, acquisitions, and strategic partnerships to address mounting financial pressures, embrace technological

Who Really Benefits from Health Care Policy Changes?
Management & Administration Who Really Benefits from Health Care Policy Changes?

Amid the heated debates in Congress over reopening the government and revising health care legislation, a cloud of confusion hangs over the public regarding the true impact of proposed changes in H.R. 1 and the extension of enhanced Advanced Premium Tax Credits (APTCs). Many Americans remain

Infant Botulism Outbreak Linked to ByHeart Formula in 2025
Clinical & Pharma Infant Botulism Outbreak Linked to ByHeart Formula in 2025

In a startling development that has sent ripples through the public health community, a multistate outbreak of infant botulism has been traced to a specific brand of powdered infant formula, raising urgent concerns among parents and caregivers nationwide. The Centers for Disease Control and

Can Probabilistic Models Redefine Malaria Treatment Failure?
Clinical & Pharma Can Probabilistic Models Redefine Malaria Treatment Failure?

In the relentless fight against malaria, particularly the deadly Plasmodium falciparum strain, late treatment failure stands as a formidable barrier to global health progress, characterized by the reappearance of malaria parasites in the bloodstream after an initially successful drug response. This

How Can Value-Based Care Transform AFib Management?
Management & Administration How Can Value-Based Care Transform AFib Management?

Imagine a healthcare system where the focus shifts from merely treating symptoms to prioritizing long-term patient outcomes, especially for complex conditions like atrial fibrillation (AFib), which affects millions and often leads to severe complications such as stroke and heart failure. This

Trump Links Tylenol to Autism, Sparks Medical Backlash
Management & Administration Trump Links Tylenol to Autism, Sparks Medical Backlash

In a bold and highly controversial announcement, President Donald Trump, alongside key White House officials, has publicly connected the use of acetaminophen—the active ingredient in Tylenol—to autism when taken during pregnancy, a claim that lacks scientific support and has triggered widespread

How Does POSTECH-Catholic Partnership Revolutionize Bio-Health?
Care Providers How Does POSTECH-Catholic Partnership Revolutionize Bio-Health?

In an era where healthcare challenges are becoming increasingly complex, the partnership between Pohang University of Science and Technology (POSTECH) and the Catholic University of Korea emerges as a transformative force in South Korea’s bio-health sector. This collaboration transcends the

Why Did the FDA Delay Sanofi’s MS Drug Tolebrutinib Approval?
Clinical & Pharma Why Did the FDA Delay Sanofi’s MS Drug Tolebrutinib Approval?

In the fast-paced realm of pharmaceutical advancements, few stories capture attention like the regulatory journey of Sanofi’s tolebrutinib, a potential game-changer for non-relapsing secondary progressive multiple sclerosis (nrSPMS). This Bruton’s tyrosine kinase (BTK) inhibitor, aimed at slowing

Why Is International Private Medical Insurance a Game-Changer?
Management & Administration Why Is International Private Medical Insurance a Game-Changer?

In an era where global mobility defines personal and professional lives, the demand for healthcare solutions that transcend borders has surged to unprecedented levels, making International Private Medical Insurance (IPMI) a vital resource. IPMI emerges as a transformative force, offering a robust

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later